In all fairness I had two stabs: one quantitative vs one qualitative, and it turns out the qualitative guess was more accurate. I'm surprised by the high mOS for the control group since I thought it would be lower than 11.3 months.
LuPSMA should now definitely be approved by the FDA and it throws into the works many exciting future possibilities, which could also include Veyonda. We still need to see the results for 1200mg NOX66, with the possibility to go up to 2400mg and to be incorporated earlier into the treatment phase along with LuPSMA. This is where the TheraP study results become important since if there is no improved in OS between LuPSMA and Cabazitaxel, then Novartis may look to Veyonda to improve OS for these patients, which would also increase the marketable value for Veyonda. So there's still a lot to look forward to.
A few more slides for those interested, which basically just tells us the same information, just in a more legible way:
- Forums
- ASX - By Stock
- NOX
- Novartis Vision trial result
Novartis Vision trial result, page-10
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.5¢ |
Change
-0.005(4.17%) |
Mkt cap ! $33.60M |
Open | High | Low | Value | Volume |
11.5¢ | 11.5¢ | 11.5¢ | $1.863K | 16.19K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 103413 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 159073 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 103413 | 0.115 |
2 | 75461 | 0.110 |
4 | 445000 | 0.105 |
5 | 233107 | 0.100 |
1 | 6000 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 159073 | 5 |
0.125 | 192466 | 5 |
0.130 | 409378 | 5 |
0.135 | 205000 | 2 |
0.140 | 237281 | 7 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online